The global autoimmune disease diagnosis market size was US$ 4.5 billion in 2021. The global autoimmune disease diagnosis market is forecast to grow to US$ 8.1 billion by 2030 by registering a compound annual growth rate (CAGR) of 9.1% during the forecast period from 2022 to 2030. 
An autoimmune disease is a condition in which the immune system attacks the body incorrectly. The immune system can distinguish between foreign cells and body cells; however, when autoimmune disease occurs, your immune system misidentifies a part of your body.  

Factors Influencing the Market
The global autoimmune disease diagnosis market is forecast to witness substantial growth in terms of revenue, owing to the increasing prevalence of the autoimmune disease. Furthermore, growing patient awareness related to the harmful effects of autoimmune disease will contribute to the growth of the autoimmune disease diagnosis market. 
Growing laboratory automation for simultaneous diagnosis of multiple diagnostic tests and rapid and error-free results, will offer ample growth opportunities for the autoimmune disease diagnosis market. In addition to that, growing healthcare expenditure across various developing and developed nations will benefit the autoimmune disease diagnosis market during the forecast period. 
Advancements in healthcare technology and infrastructure will also drive the overall autoimmune disease diagnosis market forward. On the contrary, non-penetration in the remote areas of underdeveloped countries may limit the growth of the autoimmune disease diagnosis market during the analysis timeframe.

COVID-19 Impact Analysis
In a long term, the COVID-19 pandemic has positively affected the autoimmune disease diagnosis market as the governments of various nations are investing highly in the healthcare sector. As a result, it will lead to the infrastructural development of the healthcare sector. However, the market witnessed various challenges during the initial phase of the pandemic as healthcare bodies stopped allowing cases other than COVID-19. As a result, it reduced the demand for autoimmune disease diagnoses.

Regional Analysis
Europe will hold the highest share in the autoimmune disease diagnosis market due to the rising prevalence of chronic diseases and the rapidly evolving healthcare sector in the region. Further, the growth rate of the geriatric population and the rising demand for better and more accurate diagnoses will contribute to the growth of the market. 
North America will register a substantial growth rate in the autoimmune disease diagnosis market due to high healthcare expenditure and rising digitalization across the region's healthcare segment. 
The Asia-Pacific autoimmune disease diagnosis market will also emerge as a substantial contributor due to the developing healthcare infrastructure and high unmet medical needs of the population, which will be opportunistic for the industry.

Competitors in the Market
• AESKU GROUP GMBH & CO. KG 
• Abbott 
• Thermo Fisher Scientific 
• Danaher 
• HYCOR Biomedical 
• Siemens 
• Inova Diagnostics 
• Trinity Biotech
• Bio-Rad 
• GRIFOLS 
• Other Prominent Players

Market Segmentation
The global autoimmune disease diagnosis market segmentation focuses on Product, Test, Disease, and Region. 
By Product 
• Consumables & Assay Kits
• Instruments
• Others
By Test Type 
• Routine Laboratory Tests
• Inflammatory Markers
• Autoantibodies & Immunologic Test
• Other Tests
By Disease 
• Rheumatoid Arthritis
• Systemic Lupus Erythematosus
• Sjögren’s Syndrome
• Thyroiditis
• Scleroderma
• Other Diseases
By End-User 
• Clinical Laboratories
• Hospitals
• Other End Users
By Region
● North America
o The U.S.
o Canada
o Mexico
● Europe
▪ Western Europe
o The UK
o Germany
o France
o Italy
o Spain
o Rest of Western Europe
▪ Eastern Europe
o Poland
o Russia
o Rest of Eastern Europe
● Asia Pacific
o China
o India
o Japan
o Australia & New Zealand
o ASEAN
o Rest of Asia Pacific
● Middle East & Africa (MEA)
o UAE
o Saudi Arabia
o South Africa
o Rest of MEA
● South America
o Brazil
o Argentina